NICE vs SIGN: Management of Hypothyroidism (2025) - A Clinical Comparison
This guide provides a detailed, factual comparison of the National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) guidelines for the management of hypothyroidism in adults. While there is significant alignment between the two, understanding the nuances is crucial for UK clinicians to deliver standardised, evidence-based care. This comparison focuses on the core recommendations relevant to daily practice.
See how this translates to practice: Explore our Clinical governance features, visit the Patient Safety Hub, or review Clinical Safety & Assurance for enterprise rollout.
Diagnosis and Initial Assessment
NICE (NG145)
NICE provides a clear, stepwise approach to diagnosis. The cornerstone is thyroid function testing (TFTs).
- First-line test: Measure Thyroid-Stimulating Hormone (TSH).
- Confirmatory test: If TSH is elevated, measure free thyroxine (fT4). A high TSH with a low fT4 confirms primary overt hypothyroidism.
- Subclinical Hypothyroidism (SCH): Defined as an elevated TSH with a normal fT4. NICE recommends considering a trial of levothyroxine in SCH if TSH is >10 mIU/L or if TSH is repeatedly above the reference range and the patient has symptoms suggestive of hypothyroidism.
- Thyroid peroxidase (TPO) antibodies: Testing is recommended if the aetiology is unclear, as positive antibodies increase the likelihood of progression from SCH to overt hypothyroidism.
SIGN (SIGN 161)
SIGN's approach is largely congruent with NICE but offers slightly different emphasis and thresholds.
- Diagnostic testing: Similarly, diagnosis is based on a persistently elevated TSH with a low fT4.
- Subclinical Hypothyroidism (SCH): SIGN also suggests considering treatment for SCH when TSH is >10 mIU/L. For TSH levels between the upper reference limit and 10 mIU/L, treatment may be considered if the patient is symptomatic and has positive thyroid antibodies, acknowledging the higher risk of progression.
- Antibody testing: SIGN places a stronger emphasis on TPO antibody testing in the context of SCH to aid prognostic stratification.
Key Difference & Practical Takeaway: The diagnostic criteria for overt hypothyroidism are identical. For SCH, both guidelines agree on treatment for TSH >10 mIU/L. The subtle difference lies in the management of milder SCH (TSH 4-10 mIU/L), where SIGN more explicitly links treatment consideration to the presence of both symptoms and positive antibodies, while NICE allows for a trial based on symptoms alone. In practice, antibody testing can be a useful prognostic tool in this grey area.
Treatment: Levothyroxine Therapy
Initiating Treatment and Dosing
Both NICE and SIGN are in strong agreement on the fundamentals of treatment.
- First-line therapy: Oral levothyroxine sodium is the treatment of choice for all patients.
- Starting dose: For adults under 60 with no significant cardiac disease, start with 50-100 micrograms daily. A typical starting dose is 1.6 micrograms per kilogram of body weight per day.
- Dosing in the elderly/cardiac disease: Start with a lower dose (25-50 micrograms daily) in patients over 60 or those with known cardiac disease to avoid precipitating cardiac ischaemia, with cautious titration.
- Timing of administration: Levothyroxine should be taken on an empty stomach, ideally 30-60 minutes before breakfast, and consistently at the same time each day.
Monitoring and Dose Titration
- Initial monitoring: Check TSH at 6-8 weeks after starting or changing the dose.
- Dose adjustment: Titrate the dose in 12.5-25 microgram increments based on TSH levels, repeating TFTs every 6-8 weeks until stable.
- Stable patients: Once stable, both guidelines recommend checking TSH annually.
- Treatment target: The goal is to achieve a TSH level within the reference range. NICE specifies that the patient should be clinically euthyroid and biochemically within the reference range. SIGN similarly aims for a TSH in the lower half of the reference range (0.4-2.5 mIU/L) for most patients, though this is not a rigid rule.
Key Difference & Practical Takeaway: There are no major differences in treatment protocols. Both guidelines are evidence-based and pragmatic. The annual review for stable patients is a key standard of care endorsed by both.
Special Situations and Considerations
Pregnancy and Preconception
Both guidelines are aligned on the critical importance of optimising thyroid function in women planning pregnancy and during pregnancy.
- Preconception: Women with hypothyroidism should have their dose optimised to achieve a TSH concentration below 2.5 mIU/L before conception.
- During pregnancy: Increase the levothyroxine dose empirically upon confirmation of pregnancy (often by 25-30%). This should be done without waiting for TFT results.
- Monitoring in pregnancy: Check TSH every 4-6 weeks throughout pregnancy with a target TSH within the trimester-specific reference range (if available) or below 2.5 mIU/L.
Armour Thyroid (Desiccated Thyroid Extract) and Liothyronine (T3)
This is an area of clear and important consensus.
- NICE: States that liothyronine (T3) should not be offered routinely for primary hypothyroidism due to a lack of evidence for benefit over levothyroxine monotherapy, potential cardiac risks, and higher cost. It should only be considered under specialist supervision for specific cases where levothyroxine is not tolerated. Desiccated thyroid extract is not recommended.
- SIGN: Echoes this position precisely, recommending against the routine use of T3-containing preparations due to insufficient evidence of superiority and greater risks.
Practical Takeaway: The stance on T3 and desiccated thyroid extract is unified and robust. Initiation of these therapies should be restricted to secondary care endocrinologists for exceptional circumstances, and clinicians should be prepared to counsel patients on the evidence base supporting levothyroxine as the standard of care.
Practical Clinical Management Flow
A consolidated, practical flow for managing a new patient with suspected hypothyroidism, synthesising both guidelines:
- Presentation: Patient presents with symptoms suggestive of hypothyroidism (e.g., fatigue, weight gain, cold intolerance).
- First Test: Measure TSH.
- If TSH elevated: Measure fT4.
- Overt Hypothyroidism (Low fT4): Initiate levothyroxine. Start at 50-100 mcg/day (lower if elderly/cardiac history). Advise on correct administration.
- Subclinical Hypothyroidism (Normal fT4):
- If TSH >10 mIU/L → Consider levothyroxine trial.
- If TSH 4-10 mIU/L → Check TPO antibodies. Consider trial if symptomatic, especially if antibodies are positive. Monitor TSH 6-monthly if untreated.
- Monitoring & Titration: Recheck TSH after 6-8 weeks. Titrate dose in 12.5-25 mcg increments until TSH is within the reference range and patient is clinically euthyroid.
- Long-term Management: Once stable, review clinically and check TSH annually.
Frequently Asked Questions (FAQs) for Clinicians
1. A patient's TSH is 8.5 mIU/L, they have mild symptoms, and negative antibodies. Should I treat?
Answer: This is a clinical grey area. NICE allows for a therapeutic trial based on symptoms. SIGN would be more cautious without positive antibodies. A reasonable approach is to discuss the pros (potential symptom relief) and cons (lifelong medication, need for monitoring) with the patient. A period of watchful waiting with repeat TFTs in 3-6 months is also a valid option.
2. My patient feels unwell despite a TSH in the reference range. What should I do?
Answer: First, reassess adherence and administration technique (e.g., taking with food, coffee, or other medications can impair absorption). Review for other causes of their symptoms (e.g., iron deficiency, vitamin B12 deficiency, sleep apnoea). Both guidelines strongly advise against adding liothyronine (T3) outside of a specialist setting and a recognised clinical trial.
3. How should I manage a patient who insists on "natural" desiccated thyroid extract?
Answer: Both NICE and SIGN recommend against desiccated thyroid extract due to inconsistent hormone ratios, lack of evidence, and potential safety concerns. Counsel the patient on the robust evidence base for levothyroxine. If they remain adamant, referral to an endocrinologist is appropriate, as initiation should be a specialist decision.
4. A pregnant patient on levothyroxine has a booking TSH of 3.8 mIU/L. Is an dose increase needed?
Answer: Yes. The target TSH in the first trimester is typically below 2.5 mIU/L. An increase in her levothyroxine dose (e.g., by 25-30%) is indicated, and TSH should be rechecked in 4-6 weeks.
5. Are there any differences in monitoring schedules between NICE and SIGN?
Answer: No. Both recommend checking TSH 6-8 weeks after initiation or dose change, and annually once stable. This consistency simplifies long-term management across the UK.
Source Links
- NICE Guideline NG145: Thyroid disease: assessment and management. [Last updated: March 2024. Accessed for 2025 relevance]. NICE NG145
- SIGN Guideline 161: Management of Thyroid Disease. [Published: March 2023. Accessed for 2025 relevance]. SIGN 161 (PDF)